Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients
ClinicalTrials.gov Identifier: NCT03867201
Novartis Reference Number: CAMG334A2304
Last Update: Apr 01, 2021
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
The purpose of this study is to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
Interventions
Eligibility Criteria
key inclusion Criteria:
History of at least 5 attacks of migraine
≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period
>=80% diary compliance during the baseline period
Key exclusion Criteria:
Older than 50 years of age at migraine onset
History of cluster or hemiplegic headache
Evidence of seizure or major psychiatric disorder
Cardiac or active hepatic disease
Pregnant or nursing
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]